RSS
_-The-Breakthrough-Antipsychotic-That-Could-Change-Everything.jpg?1729528747 "KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg")
On a weekly basis, we present updates on clinical psychiatry as another opportunity to earn CME credit. What were the most listened to episodes of 2022? We'll start the countdown at #10.
#10. 7 Tips for a Better Sleep
A new app for insomnia might also lift depression. We show you how it works and end with 7 practical tips to share with your patients who have insomnia.
Chris Aiken, MD, Kellie Newsome, PMHNP, and Jesse Koskey, MD have disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Published On: 03/14/2022
Duration: 30 minutes, 24 seconds
Related Article: “A Prescription App for Insomnia,” The Carlat Psychiatry Report, March 2022
Listen to the episode here.
Methamphetamine is the second most abused drug in the U.S. We bring you up to speed on the basics in this episode.
Chris Aiken, MD, Kellie Newsome, PMHNP, and David A. Moltz, MD have disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Published On: 02/21/2022
Duration: 20 minutes, 52 seconds
Related Article: “A Novel Treatment for Methamphetamine Use Disorder,” The Carlat Psychiatry Report, February 2022
Listen to the episode here.
#8. New Options for Treatment Resistant Bipolar Depression
A recent paper lists 5 therapies for treatment-resistant depression, but the research keeps rolling in, and we bring you 2 more to add to the list.
Chris Aiken, MD, Kellie Newsome, PMHNP, and Tammas Kelly, MD have disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Published On: 04/18/2022
Duration: 20 minutes, 15 seconds
Related Article: “Thyroid Augmentation in Bipolar Disorder,” The Carlat Psychiatry Report, April 2022
Listen to the episode here.
#7. What Works for Treatment Resistant Anxiety?
Silexan, an extract from Lavender with pharmaceutical properties, is one of only two treatments with a large effect size in generalized anxiety disorder. We rank all the treatments by strength and look to see if any of them can work when the SSRIs do not.
Chris Aiken, MD and Kellie Newsome, PMHNP have disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Published On: 8/22/2022
Duration: 25 minutes, 48 seconds
Listen to the episode here.
#6 . Treating Borderline Personality Disorder in Emergency Settings
Borderline personality disorder can be complicated to treat, especially in frantic and high stress settings like the emergency department or inpatient psychiatric unit. In today’s episode, we’ll address the best practices for managing patients with borderline personality disorder in emergency settings.
Victoria Hendrick, MD, Zachary Davis, BS, and Victor Hong, MD, have disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Published On: 03/28/2022
Duration: 27 minutes, 57 seconds
Related Article: “Borderline Personality Disorder in the ED,” The Carlat Hospital Psychiatry Report, January/February/March 2022
Listen to the episode here.
#5. 12 New Findings on Quetiapine
12 clinically relevant findings from the past 3 years on quetiapine (Seroquel), including new side effects, dosing strategies, withdrawal phenomena, and new uses in bipolar with OCD.
Chris Aiken, MD, Kellie Newsome, PMHNP, and Paul Riordan, MD, have disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Published On: 06/6/2022
Duration: 20 minutes, 27 seconds
Referenced Article: “Quetiapine Reconsidered,” The Carlat Child Psychiatry Report, June 2022
Listen to the episode here.
#4. Schizophrenia: Catching Up to New Guidelines
The new APA guidelines on schizophrenia go above and beyond the usual standards. Brian Miller shows us how to catch up.
Chris Aiken, MD, Kellie Newsome, PMHNP, and Brian Miller, MD, PhD, MPH, have disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Published On: 02/14/2022
Duration: 25 minutes, 58 seconds
Related Article: “Raising the Bar in Schizophrenia Treatment,” The Carlat Psychiatry Report, February 2022
Listen to the episode here.
#3. A New Option for Bipolar Depression
Lumateperone (Caplyta) just got FDA approved for bipolar depression. Find out how it compares to other atypical antipsychotics.
Chris Aiken, MD, and Kellie Newsome, PMHNP, have disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Published On: 01/24/2022
Duration: 24 minutes, 09 seconds
Listen to the episode here.
#2. 6 Reasons to Use Tricyclics
Tricyclics are much better tolerated than their reputation suggests, and countdown 6 reasons to use them, from melancholic depression to irritable bowel syndrome.
Chris Aiken, MD, Kellie Newsome, PMHNP, Nassir Ghaemi, MD, MPH, and Joe Goldberg, MD, have disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Published On: 05/23/2022
Duration: 14 minutes, 16 seconds
Listen to the episode here.
#1. What Works in Bipolar Depression
From psychotherapy to ECT, pramipexole to lamotrigine, a walk through 20 therapies for bipolar depression.
Chris Aiken, MD, and Kellie Newsome, PMHNP, have disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Published On: 04/11/2022
Duration: 25 minutes, 18 seconds
Related Article: “A Practical Guide to Light Therapy,” The Carlat Psychiatry Report, November 2019
Listen to the episode here.
There you have it. Looks like treatment options for bipolar depression are at the top of clinicians' minds. If you want to support the podcast and earn CME credits for listening to these episodes, purchase a podcast subscription here.
